Aurinia Pharmaceuticals AUPH Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 88.5%+0.5pp | 88%-4.0pp | 91.9%-3.8pp | 95.8%-1.8pp | |
| Operating margin | 37.1%+39.1pp | -2%+50.2pp | -52.2%+30.9pp | -83.2%+313pp | |
| Net margin | 101.5%+99.0pp | 2.4%+46.9pp | -44.5%+36.3pp | -80.7%+316pp | |
| Returns | |||||
| Return on equity | 59.9%+58.4pp | 1.5%+21.4pp | -19.9%+4.5pp | -24.5%+16.4pp | |
| Return on invested capital | 21.4%+22.5pp | -1.1%+23.0pp | -24.1%+14.6pp | -38.8%+51.7pp | |
| Efficiency | |||||
| Asset turnover | 0.4×0.0× | 0.4×+0.1× | 0.3×+0.1× | 0.3×+0.2× | |
| Liquidity | |||||
| Current ratio | 5.2×+0.7× | 4.6×-0.9× | 5.5×-4.1× | 9.6×-3.0× | |
| Leverage | |||||
| Debt-to-equity | 0.2×-0.1× | 0.2×0.0× | 0.3×+0.3× | 0×0.0× | |
| Net debt / EBITDA | 0.1×-0.6× | 0.7×— | —— | —— | |
| Per Share | |||||
| Book value per share | $4.19+62.3% | $2.58-2.1% | $2.64-7.6% | $2.86-22.9% | |
| Valuation | |||||
| Market capitalization | $2.1B+63.6% | $1.29B0.0% | $1.29B+108% | $617.84M-81.1% | |
| Price / earnings | 7.3×-216× | 223.5×— | —— | —— | |
| Price / sales | 7.4×+2.0× | 5.5×-1.9× | 7.3×+2.7× | 4.6×-67.1× | |
| Price / book | 3.6×+0.2× | 3.4×0.0× | 3.4×+1.9× | 1.5×-5.3× | |
| EV / EBITDA | 17×-70.8× | 87.8×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aurinia Pharmaceuticals's profit margins?
- Aurinia Pharmaceuticals (AUPH) runs a 89.7% gross margin and a 41.7% operating margin, with a 100.0% net margin.
- Where do Aurinia Pharmaceuticals's ratios come from?
- Every ratio is computed from Aurinia Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
